News

About 500 patients will be enrolled in the trial, which will compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone. The company intends to

Under the deal, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX technology to improve the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead

Regulus Therapeutics’ Phase I study is being conducted in the Netherlands. Primary objective of the Phase I study is to assess the safety and tolerability of RG-101, while

The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. US patent number 8,664,189, will expire in 2029. The notice of

In the initial term of the agreement Metabolon will carry out small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules

The region most affected is Bangalore and North Carolina, particularly in the areas of biostatistics and statistical programming, following the award of large functional service provision (FSP) contracts

The company has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which

These product candidates – two GITR agonists and a CTLA-4 antagonist – target cell-surface checkpoint proteins that control immune responses. They are part of Agenus’ recent acquisition of

Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. The inclusion of Soltamox on the Medicare Part D Formulary allows broad,